[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366826-105":59,"doc-detail-366826-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-genetics-and-response-to-oncolytic-virus-treatment-for-ovarian-cancer","Cancer genetics and response to oncolytic virus treatment for ovarian cancer","","Ovarian cancers are characterized as poorly immunogenic tumors with low response rates to current immunotherapies and frequent resistance to chemotherapy. Oncolytic viruses offer a multifactorial approach by enhancing immune recovery and promoting immune infiltration while helping the immune system recognize and target evasive tumors. This review highlights four extensively tested oncolytic viruses for ovarian cancer: vaccinia viruses, vesicular stomatitis virus, herpes simplex 1, and adenoviruses. It discusses their development as monotherapies, emerging combinational strategies to improve outcomes, and how ovarian cancer genetics can shape viral response and guide genetic modifications that increase specificity and efficacy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-genetics-and-response-to-oncolytic-virus-treatment-for-ovarian-cancer/366826/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-genetics-and-response-to-oncolytic-virus-treatment-for-ovarian-cancer/366826.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are ovarian cancers challenging to treat with current immunotherapies and chemotherapy?","Question",{"text":112,"@type":113},"Ovarian cancers are often poorly immunogenic, leading to low response rates to immunotherapies. They also frequently develop resistance to chemotherapies, contributing to limited long-term outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which oncolytic viruses are emphasized in this review for ovarian cancer?",{"text":117,"@type":113},"The review focuses on vaccinia viruses, vesicular stomatitis virus, herpes simplex 1, and adenoviruses, each studied in preclinical models and clinical trials for ovarian cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"How can cancer genetics affect response to oncolytic virus therapy?",{"text":121,"@type":113},"Genetic mutation profiles of ovarian cancer cells can influence how effectively viruses can infect and trigger responses. This understanding can drive genetic modifications of oncolytic viruses to improve cancer specificity and therapeutic efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366826,1790179358,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","PHARMACOGENOMICS  \n2025, VOL. 26, NOS. 13–14, 529–542  \n[https://doi.org/10.1080/14622416.2025.2580271](https://doi.org/10.1080/14622416.2025.2580271)  \nREVIEW  \nCancer genetics and response to oncolytic virus treatment for ovarian cancer  \nErin L. Fletcher a,b, Alison O. Cudmore a,b and Barbara C. Vanderhyden a,b  \naDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada; bCancer Research Program, Ottawa Hospital Research Institute, Ottawa, Canada  \nABSTRACT  \nOvarian cancers (OCs) are often defined as poorly immunogenic tumors that have low response rates to current immunotherapies and frequently develop resistance to chemotherapies. Oncolytic viruses (OVs) are an emerging therapeutic approach that is favored due to its multifactorial mechanism of action; OVs aim to enhance immune cell recovery and infiltration into the tumor, in addition to assisting the immune system to identify and target evasive tumors. While many different OVs have been studied, this review focuses on the four that have been extensively tested in preclinical models and clinical trials with OC patients: vaccinia viruses, vesicular stomatitis virus, herpes simplex 1, and adenoviruses. We will first explore how these viruses have been developed, modified and tested as monotherapies in OCs, with limited success. The various combinatorial approaches involving OVs that are currently being investigated to improve the outcomes for OC patients will then be addressed. Attention will be given to how the genetics of OC cells may influence response to OVs and how that has led to genetic modifications of OVs that improve the cancer specificity and efficacy of these therapies.  \nPLAIN LANGUAGE SUMMARY  \nThis review explores the impact of both viral and cancer cell genetics on the success of oncolytic virus (OV) therapy in ovarian cancers. Herein, we evaluate published studies on the four most commonly used viruses in ovarian cancer, which are vaccinia virus, adenovirus, herpes simplex virus 1, and vesicular stomatitis virus. While each of these viruses has been tested in clinical trials, efficacy in patients has been somewhat limited. This maybe due in part to the lack of consideration of cancer genetics, since cancers with certain mutations may be better candidates for viral infection. Additionally, many OV therapies have focused on delivery as monotherapies. However, combinational approaches, including pairing OVs with chemotherapies, other drugs, or even other OVs, is becoming a new focus for the field and may substantially improve patient outcomes.  \nARTICLE HISTORY  \nReceived 11 July 2025 Accepted 15 October 2025  \nKEYWORDS  \nOncolytic virus; ovarian cancer; vaccinia virus; herpes simplex virus 1; vesicularstomatitis virus; adenovirus; combination therapy  \n1. Introduction  \nDespite many advancements in the treatment of other cancers, the long-term survival rate for ovarian cancer (OC) patients has not improved significantly in the past 30 years, with 5-year survival remaining below 45%[1,2]. There are two main factors that contribute to this poor survival rate: delays in the detection and diagnosis of OC, and development of tumor resistance to current treatments. There are currently no effective screening programs for OCs. Instead, transvaginal ultrasounds are used to detect tumors once a patient starts to exhibit symptoms; however, due to the vagueness of these symptoms (i.e., bloating, loss of appetite, pelvic or abdominal pain, feeling full quickly after eating, and urinary changes) [3], they are often overlooked. The result is that most women are not tested until tumors have progressed into advanced stages with poor prognosis. Once tumors are identified, the current standard of care includes surgical debulking to remove the tumor mass and platinum-based chemotherapy [4]. However, while most patients will initially respond to chemotherapy, up to 80% will experience a recurrence depending on their stage [5].  \nOCs are divided into d","cbCaimtHh74FoDzJ","https://ap.wps.com/l/cbCaimtHh74FoDzJ","pdf",5566722,14,"English","# Introduction\n## Ovarian cancer burden and current treatment challenges\n## Ovarian cancer classification and subtypes\n## Genetic mutations influencing therapeutic efficacy\n# Abstract and Plain Language Summary\n## Oncolytic virus mechanisms and therapeutic rationale\n## Focus viruses and combinational approaches\n## Genetics-guided viral engineering","[{\"question\":\"Why are ovarian cancers challenging to treat with current immunotherapies and chemotherapy?\",\"answer\":\"Ovarian cancers are often poorly immunogenic, leading to low response rates to immunotherapies. They also frequently develop resistance to chemotherapies, contributing to limited long-term outcomes.\"},{\"question\":\"Which oncolytic viruses are emphasized in this review for ovarian cancer?\",\"answer\":\"The review focuses on vaccinia viruses, vesicular stomatitis virus, herpes simplex 1, and adenoviruses, each studied in preclinical models and clinical trials for ovarian cancer.\"},{\"question\":\"How can cancer genetics affect response to oncolytic virus therapy?\",\"answer\":\"Genetic mutation profiles of ovarian cancer cells can influence how effectively viruses can infect and trigger responses. This understanding can drive genetic modifications of oncolytic viruses to improve cancer specificity and therapeutic efficacy.\"}]","Cancer genetics and response to oncolytic virus treatment for ovarian cancer | PDF",1790167799,35]